{
  "eval_id": "S33",
  "eval_file": "evals/single/S33.json",
  "timestamp": "2025-09-18T17:14:44.207871+00:00",
  "model": "gpt-4.1",
  "temperature": 0.6,
  "rep_input": "Patient HR+/HER2- progressed after CDK4/6; what key label-based caveats should I discuss?",
  "model_output": "After progression on CDK4/6 in HR+/HER2- disease, the on-label options depend on prior endocrine therapies, performance status, and presence of visceral disease. Please send the SmPC or EMA summary for any product youâ€™re referencing so I can ensure our discussion is strictly on-label."
}